April 29, 2025

Richard Pazdur, MD, Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine

During the 2025 American Association for Cancer Research (AACR) Annual Meeting, Richard Pazdur, MD, accepted an award and gave remarks during the meeting’s Opening Ceremony.

The ASCO Post

April 29, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post

April 29, 2025

AACR 2025: Novel Targeted Therapy Under Study in Selected Patients With Advanced Solid Tumors

According to the results of a phase I trial, the first-in-class covalent Werner helicase inhibitor (RO7589831) demonstrated early signals of efficacy as well as general tolerability in patients with a...

The ASCO Post

April 29, 2025

RadSearch Transforms Radiology Report Retrieval 

RadSearch could enhance radiologists' ability to find precedent cases.

Conexiant

April 28, 2025

Could a New Urine Test Detect Prostate Cancer? 

Researchers combined spatial transcriptomics with machine learning to develop a urine-based prostate cancer test with 92% accuracy, outperforming traditional PSA testing.

Conexiant

April 25, 2025

Omission of Endocrine Therapy in Estrogen Receptor–Low, Early-Stage Breast Cancer

In a study reported in the Journal of Clinical Oncology, Choong et al looked at whether the omission of endocrine therapy in patients with estrogen receptor–low (1%–10% on immunohistochemistry), early...

The ASCO Post

April 25, 2025

FDA Approves Anti–PD-1 Antibody for Nasopharyngeal Cancer

The FDA has approved the humanized IgG1 monoclonal anti–PD-1 antibody penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic ...

The ASCO Post

April 24, 2025

W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of The Ohio State’s James Cancer Hospital and Solove Research Institute

Former Director of NCI, Dr. W. Kimryn Rathmell, renowned for cancer research, appointed CEO of The Ohio State University Comprehensive Cancer Center, promising visionary leadership and a commitment to health equity.

The ASCO Post

April 24, 2025

Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer

Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lun...

The ASCO Post